Clinical and experimental rheumatology最新文献

{"title":"The expression of Siglec-10 on naive B cells is involved in the pathology of systemic lupus erythematosus.","authors":"Bomiao Ju, Jing Luo, Nan Hu, Jing Zhang, Li Zhu, Qian Li, Yanhua Wang, Jing Huang, Qi An, Qianyun Xu, Zhiming Hao, Dan Pu, Xiaohong Lv, Xin Li, Yongwei Huo, Baojun Zhang, Lan He","doi":"10.55563/clinexprheumatol/hlnpiz","DOIUrl":"10.55563/clinexprheumatol/hlnpiz","url":null,"abstract":"<p><strong>Objectives: </strong>Previous studies have reported the expansion of CD19+Siglec-10+ B cells in systemic lupus erythematosus (SLE) patients. However, the composition of this cell population, phenotype and characteristics are still unknown.</p><p><strong>Methods: </strong>We examined this memory B-cell subset's composition and phenotype and determined the SYK and AKT phosphorylation levels by flow cytometry. Additionally, we explored the relationship between Siglec-10 expression on B-cell subsets and clinical manifestations.</p><p><strong>Results: </strong>Our results indicated elevated levels of Siglec-10 on naive B cells in active SLE patients. Compared with healthy controls (HCs) and inactive SLE patients, the Siglec-10+ B cells in active SLE patients exhibited elevated CD40 and CD21low levels. The levels of Siglec-10 on naive B cells were positively correlated with the proportion of CD21low double negative (DN) B cells and the SLEDAI-2K score.</p><p><strong>Conclusions: </strong>The results indicate that the upregulation of Siglec-10+/naive B cells may function as a feedback mechanism to regulate B cell hyperreactivity. Monitoring the proportion of Siglec-10+/naive B cells may contribute to the evaluation of disease progression in SLE.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":"507-516"},"PeriodicalIF":3.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142876354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive and diagnostic biomarkers for cytomegalovirus infection in patients with rheumatic musculoskeletal diseases treated by high-dose glucocorticoid therapy: multicentre, prospective cohort study.","authors":"Hirohiko Sueki, Kazuteru Noguchi, Bunki Natsumoto, Keishi Fujio, Yutaro Hayashi, Yuko Kaneko, Takahisa Gono, Kuninobu Wakabayashi, Haruka Ito, Takahiko Yoshimoto, Akatsuki Kokaze, Takemi Otsuki, Yurika Shimizu, Tatsuo Ito, Koh Okamoto, Shu Okugawa, Kyoji Moriya, Kiyoshi Matsui","doi":"10.55563/clinexprheumatol/th30zv","DOIUrl":"10.55563/clinexprheumatol/th30zv","url":null,"abstract":"<p><strong>Objectives: </strong>The incidence of cytomegalovirus (CMV) infection or disease in patients with rheumatic musculoskeletal diseases is reported to be 2%. Over half received pulsed methylprednisolone, and some experienced a fatal outcome. In this study, we aimed to explore predictive and diagnostic biomarkers for CMV infection or disease in such patients and compare them with biomarkers reported for immune reconstitution inflammatory syndrome (IRIS) in people with HIV.</p><p><strong>Methods: </strong>In this multicentre prospective cohort study, we collected blood and saliva samples from 38 patients with rheumatic musculoskeletal disease before initiating high-dose glucocorticoid therapy, at the start of glucocorticoid tapering, at the onset of CMV infection, and 4 weeks later. Peripheral blood cell counts, flow cytometry for CD4, CD8, and Tregs, ELISA for cytokine/chemokine panels, and measurements of herpesvirus-derived DNA in saliva were performed.</p><p><strong>Results: </strong>Lower white blood cells, CD4+ cells, IL-6, and interferon-γ levels and higher interferon-inducible protein (IP)-10 and granulysin levels at baseline could be predictive biomarkers for CMV infection. Furthermore, lower platelet counts and higher IL-10, IP-10, granulysin, TNF-a, IL-1ra, and IL-15 levels at the onset of CMV infection were found as diagnostic biomarkers for CMV infection. EBV, human herpes virus (HHV)-6, and HHV-7 DNA levels in the saliva were significantly increased after high-dose glucocorticoids, regardless of CMV infection.</p><p><strong>Conclusions: </strong>We identified predictive and diagnostic biomarkers for CMV infection after high-dose glucocorticoid therapy for rheumatic musculoskeletal diseases. While similarities with IRIS biomarkers in patients living with HIV were observed, complete agreement could not be confirmed.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":"497-506"},"PeriodicalIF":3.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143188469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rheumatoid arthritis-associated interstitial lung disease: clinical characteristics and mortality in a large single-centre cohort.","authors":"Rajaie A Namas, Mahmoud El-Kaissi, Esat Memisoglu, Saniya Khan, Sarah S Al Qassimi, Mohammed A Omair, Jeffery Chapman, Oshin Kanwar, Ahlam M Almarzooqi, Jamal A Al Saleh, Asia Mubashir, Mohamed F Elarabi, Dinesh Khanna","doi":"10.55563/clinexprheumatol/d8m0xv","DOIUrl":"10.55563/clinexprheumatol/d8m0xv","url":null,"abstract":"<p><strong>Objectives: </strong>Interstitial lung disease (ILD) is a severe pulmonary complication observed in Rheumatoid Arthritis (RA) patients and is a leading cause of mortality within this population. The objective of this study is to provide a comprehensive comparative analysis of a real-world observational cohort, distinguishing between patients with and without ILD. This analysis encompasses various aspects including sociodemographic, clinical, biological, and radiological factors.</p><p><strong>Methods: </strong>A retrospective chart review was conducted from April 2015 to April 2021, including all patients diagnosed with RA according to the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification. Demographics, clinical characteristics, laboratory markers, and treatment data were retrieved from electronic medical records. Multiple regression analyses were performed to investigate the risk factors associated with ILD in RA patients.</p><p><strong>Results: </strong>The study enrolled 153 RA patients diagnosed with RA, with 53 having RA-ILD and 100 without ILD. Multivariable analyses were conducted, treating ILD presence in RA patients as the dependent variable in RA patients, revealing notable associations. Smoking status (OR=8.82), presence of rheumatoid factor (OR=4.98), elevated Disease Activity Score-28 for RA with CRP (DAS-CRP) levels (OR=2.05) were all significantly associated with ILD presence in RA patients.</p><p><strong>Conclusions: </strong>This study underscores the substantial association between serologies, disease activity scores, and smoking history, contributing to the heightened susceptibility to ILD in RA patients. Recognising these risk factors and instituting systematic monitoring of routine disease activity metrics would facilitate targeted strategies for early detection and intervention.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":"425-434"},"PeriodicalIF":3.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143398515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"C-reactive protein thresholds for discriminating active disease in axial spondyloarthritis: should we lower them?","authors":"Sara Alonso-Castro, Pablo González Del Pozo, Paula Alvarez, Norma Calleja, Stefanie Burger, Rubén Queiro","doi":"10.55563/clinexprheumatol/lelu7p","DOIUrl":"10.55563/clinexprheumatol/lelu7p","url":null,"abstract":"<p><strong>Objectives: </strong>Although C-reactive protein (CRP) is the main inflammatory biomarker used for axial spondyloarthritis (axSpA) assessment, its sensitivity for detecting active disease is low. We aimed to analyse CRP thresholds capable of discriminating across disease activity states in axSpA.</p><p><strong>Methods: </strong>Two hundred consecutive patients with axSpA were recruited (with/without biologics). Discriminative CRP thresholds were determined by the Youden index, while their sensitivity/specificity was evaluated by the area under the ROC curve (AUROC). Sensitivity analyses were performed based on exposure to biologic drugs.</p><p><strong>Result: </strong>One hundred and twenty-two men and 78 women were included, mean age 43.5±11.6 years, mean age at diagnosis 34±10.7 years, average disease duration 8.6±6.5 years. Median CRP 0.20 mg/dl (IQR 0.10-0.40). A CRP ≥0.25 mg/dl discriminated the population with high/very high disease activity [AUROC 0.71; OR 3.9, p<0.001]. This threshold rose to CRP ≥0.35 mg/dl [AUROC 0.72; OR 10.4, p<0.001] among patients without biological therapy, remaining at ≥0.25 mg/dl [AUROC 0.70; OR 4.02, p<0.001] in those exposed to these therapies. The standard inflammatory CRP value (≥0.5 mg/dl) was highly specific (0.90) but poorly sensitive (0.35) in detecting high/very high disease activity states, making it less discriminatory than previous thresholds.</p><p><strong>Conclusions: </strong>Our results suggest adopting lower than standard CRP cut-off values for a better assessment of both the global activity of the disease and a better interpretation of the composite activity indices used in axSpA.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":"472-476"},"PeriodicalIF":3.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143188355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term efficacy of sarilumab on the progression of interstitial lung disease in rheumatoid arthritis: the KEIO-RA cohort and literature review.","authors":"Koji Suzuki, Mitsuhiro Akiyama, Yuko Kaneko","doi":"10.55563/clinexprheumatol/pc2kq1","DOIUrl":"10.55563/clinexprheumatol/pc2kq1","url":null,"abstract":"<p><strong>Objectives: </strong>To clarify the impact of sarilumab (SAR) on the progression of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA).</p><p><strong>Methods: </strong>We conducted a retrospective review of all consecutive RA patients from the KEIO-RA cohort who visited our institution between 2018 and 2024 and received SAR treatment. Patients were followed for 24 months from the initiation of SAR. The primary outcome was the rate of progression of ILD as assessed by high-resolution computed tomography (HRCT). We also conducted a literature review regarding the efficacy of SAR on RA-ILD in PubMed, Web of Science, and Scopus databases.</p><p><strong>Results: </strong>Among 123 cases, 21 (17.1%) had ILD. The median age at SAR initiation was 56 years, and 71.4% were female. Except for 6 cases, SAR was administered as monotherapy via subcutaneous injection at 200 mg every two weeks. During SAR treatment, 18 cases (85.7%) exhibited stable HRCT findings, coupled with improvements in arthritis. Two cases with NSIP and OP patterns demonstrated improvements in both HRCT findings and arthritis post-SAR treatment. One case experienced an exacerbation of ILD at 18 months, with worsening arthritis observed prior to the deterioration of ILD. Serum KL-6 levels also improved or remained stable after SAR initiation, except in one case of ILD exacerbation. There were no adverse events, including serious infections, during the observation period. Additionally, our literature review identified a case of RA-ILD treated with SAR and achieved remission of arthritis and ILD.</p><p><strong>Conclusions: </strong>In our study, SAR exhibited encouraging efficacy in stabilising RA-ILD in most cases.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":"451-458"},"PeriodicalIF":3.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142876347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Histopathologic evidence that hallux valgus enthesitis does not elicit nail inflammation: is the nail-enthesitis theory still valid?","authors":"Christophe Perrin, Michael Coutts","doi":"10.55563/clinexprheumatol/j5x72c","DOIUrl":"https://doi.org/10.55563/clinexprheumatol/j5x72c","url":null,"abstract":"","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":"43 3","pages":"550-551"},"PeriodicalIF":3.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143613757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ankylosing spondylitis and atrial fibrillation: a contemporary overview.","authors":"Christos S Konstantinou, Maria Karakosta, Aliki I Venetsanopoulou, Panagiotis Korantzopoulos, Paraskevi V Voulgari","doi":"10.55563/clinexprheumatol/ue8sp5","DOIUrl":"10.55563/clinexprheumatol/ue8sp5","url":null,"abstract":"<p><p>Atrial fibrillation (AF) is the most common arrhythmia in clinical practice and it is associated with increased morbidity and mortality. AF is linked with inflammatory signalling while inflammation and oxidative stress promote atrial remodelling, favouring the development and perpetuation of the arrhythmia. On the other hand, ankylosing spondylitis (AS) is considered a chronic inflammatory rheumatic condition with flares and remissions that affects the axial skeleton and mainly young people. AS has been associated with an increased risk of valvular and aorta disease but its relationship with AF has not been studied well. Recent epidemiological evidence indicates an association between AS and AF. This brief review provides a concise overview of all available data regarding the association between AS and AF including the predictive role of electrocardiographic and echocardiographic markers. Several unresolved issues including the thromboembolic risk in this setting and the potential role of anti-inflammatory interventions are also discussed.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":"526-532"},"PeriodicalIF":3.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing IgG4-related autoimmune pancreatitis with contrast-enhanced ultrasonography based on time-intensity curve: a single-centre prospective study.","authors":"Minhui Lu, Hui Wang, Yiwen Wang, Yanfeng Zhang, Xi Zheng, Yufei Guo, Huiqiong Zhou, Lichun An, Jian Zhu","doi":"10.55563/clinexprheumatol/evg4tn","DOIUrl":"10.55563/clinexprheumatol/evg4tn","url":null,"abstract":"<p><strong>Objectives: </strong>The aim of this study was to investigate the changes in various parameters of contrast-enhanced ultrasound (CEUS) before and after treatment in patients with IgG4-related autoimmune pancreatitis (IgG4-AIP), and to identify potential indicators that can assist in evaluating disease activity.</p><p><strong>Methods: </strong>In this prospective study, we enrolled patients diagnosed with IgG4-AIP from June 2021 to November 2022. Demographic characteristics, clinical features, laboratory tests were recorded. Baseline and follow-up, conventional ultrasound and CEUS were conducted. Additionally, a region of interest (ROI) within lesions, pancreatic head, pancreatic body, and pancreatic tail was taken to draw time-intensity curves (TIC) and parameters of TIC were recorded and analysed.</p><p><strong>Results: </strong>Seventy-three active IgG4-AIP patients were enrolled. Follow-up, a notable decrease in the size of the pancreatic lesion was observed with a reduction in the maximum diameter from 4.3 ± 2.0 cm to 1.7 ± 1.6 cm (p=0.01). The results revealed a statistically significant increase in peak intensity (PI) in the head, body, and tail regions of the pancreas (p<0.001), along with a significant rise in the area under the curve (AUC) in the tail region of the pancreas (p=0.029) after treatment compared to baseline. In contrast, no statistically significant differences were observed in other parameters of TIC. A significant increase of PI was observed in 12 patients with diffuse IgG4-AIP following treatment. Following treatment, there was a significant increase in PI in the focal area among the 12 patients with focal lesions.</p><p><strong>Conclusions: </strong>CEUS based on TIC holds great potential for assessing response to treatment in patients with IgG4 AIP.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":"410-417"},"PeriodicalIF":3.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extensive bone infarcts in an asymptomatic patient with systemic lupus erythematosus.","authors":"Georgios A Drosos, Theodora E Markatseli, Paraskevi V Voulgari, Alexandros A Drosos","doi":"10.55563/clinexprheumatol/ccdggq","DOIUrl":"10.55563/clinexprheumatol/ccdggq","url":null,"abstract":"","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":"546"},"PeriodicalIF":3.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic lupus erythematosus: one year in review 2025.","authors":"Angela Elia, Dina Zucchi, Ettore Silvagni, Marco Oliva, Giancarlo Cascarano, Chiara Cardelli, Benedetta Ciribè, Alessandra Bortoluzzi, Chiara Tani","doi":"10.55563/clinexprheumatol/m0pi1k","DOIUrl":"https://doi.org/10.55563/clinexprheumatol/m0pi1k","url":null,"abstract":"<p><p>This review highlights key advancements in systemic lupus erythematosus (SLE) research during 2024, covering pathogenesis, novel therapies, biomarkers, and clinical outcomes. Notable findings include new insights into immune dysregulation, promising therapeutic targets, and real-world data confirming the efficacy of anifrolumab and belimumab. Advances in biomarkers enhance disease monitoring, while multidisciplinary approaches improve reproductive outcomes and quality of life. These developments contribute to refining SLE treatment strategies and patient management.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":"43 3","pages":"397-406"},"PeriodicalIF":3.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143613759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}